Overview

Diabetic kidney disease is expected to surpass all other diabetes-related complications in morbidity and mortality. In this session, faculty will review current data on the renoprotective properties of SGLT2 inhibitors and explain the guideline recommendations for their use in patients with type 2 diabetes and kidney disease. 

*Please note that any data, indications and guidelines presented in this activity are current as of the original recording on 12/4/2019, and they are subject to change as new information is published.  

Learning Objectives

  • Explain current data surrounding the renoprotective properties of SGLT2 inhibitors
  • Review current guideline recommendations for using SGLT2 inhibitors in patients with T2DM and kidney disease
  • Develop individualized treatment plans for patients with T2DM and kidney disease  

Faculty

Melanie Hoenig, MD

Associate Professor
Harvard Medical School
Boston, MA 

Charles Vega, MD, FAAFP

Health Sciences Clinical Professor
UC Irvine Department of Family Medicine
Assistant Dean for Culture and
Community Education
Executive Director
UC Irvine Program in Medical Education for the Latino Community
UC Irvine School of Medicine
Irvine, CA 

Disclosures

The following financial relationships have been disclosed by faculty

Melanie Hoenig, MD

No financial relationships disclosed. 

Charles Vega, MD, FAAFP

No financial relationships disclosed. 


Non-faculty contributors involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships. 


CME/CE Information

AMA PRA Category 1 Credits

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  


Designation Statement

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

AANP

Accreditation Statement

The Annenberg Center for Health Sciences is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 040207. 


Designation Statement

This program is designated for up to 1.00 contact hour, which includes 0.66 hour of pharmacology. Program ID# 5813.  

Instructions for Obtaining Credit

Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 2 out of the 3 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen.

Commercial Supporter

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Education Partner

pmiCME


Fine Print

Internet Explorer (version 9.0 and above) is the minimum supported browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

pmiCME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of pmiCME to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

pmiCME Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. pmiCME, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. pmiCME is the accredited provider for this activity.

Disclosures and Conflict of Interest
pmiCME requires all individuals in a position to influence educational content for pmiCME-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. pmiCME assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by pmiCME or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.